Format
Items per page
Sort by

Send to:

Choose Destination

Results: 7

Related Articles by Review for PubMed (Select 21488082)

1.

Racial differences in hepatitis C treatment eligibility.

Melia MT, Muir AJ, McCone J, Shiffman ML, King JW, Herrine SK, Galler GW, Bloomer JR, Nunes FA, Brown KA, Mullen KD, Ravendhran N, Ghalib RH, Boparai N, Jiang R, Noviello S, Brass CA, Albrecht JK, McHutchison JG, Sulkowski MS; IDEAL Study Team.

Hepatology. 2011 Jul;54(1):70-8. doi: 10.1002/hep.24358.

2.
3.

Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.

Katz LH, Goldvaser H, Gafter-Gvili A, Tur-Kaspa R.

Cochrane Database Syst Rev. 2012 Sep 12;9:CD008516. doi: 10.1002/14651858.CD008516.pub2. Review.

PMID:
22972122
4.

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.

Manns MP, Markova AA, Calle Serrano B, Cornberg M.

Liver Int. 2012 Feb;32 Suppl 1:27-31. doi: 10.1111/j.1478-3231.2011.02725.x. Review.

PMID:
22212568
5.

Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N.

Health Technol Assess. 2007 Mar;11(11):1-205, iii. Review.

6.

Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.

Perry CM.

Drugs. 2012 Mar 26;72(5):619-41. doi: 10.2165/11208370-000000000-00000. Review.

PMID:
22439668
7.

Hepatitis C in African Americans.

Saab S, Jackson C, Nieto J, Francois F.

Am J Gastroenterol. 2014 Oct;109(10):1576-84; quiz 1575, 1585. doi: 10.1038/ajg.2014.243. Epub 2014 Sep 2. Review.

PMID:
25178700
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk